AMP Makes Three Trades in its Hypo Fund


Last Wednesday, August 30th, AMP trimmed its largest position by selling shares in Fibrogen (FGEN). At the time of the sale the position was up more than 150%. FGEN remains the biggest position in the AMP Hypothetical Fund.

Today, AMP also started a position in Nabriva Therapeutics (NBRV) ahead of its Phase 3 Lefamulin - LEAP 1 study readout in Moderate to severe Community Acquired Bacterial Pneumonia (CABP). We are cautiously optimistic about ahead of the results of this study.

Lastly, AMP also added to its CLSD position today by purchasing shares on a down day for the company.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon